M
Michaela Reiser
Researcher at University of Erlangen-Nuremberg
Publications - 12
Citations - 325
Michaela Reiser is an academic researcher from University of Erlangen-Nuremberg. The author has contributed to research in topics: Rheumatoid arthritis & Tapering. The author has an hindex of 5, co-authored 11 publications receiving 258 citations. Previous affiliations of Michaela Reiser include University of Würzburg.
Papers
More filters
Journal ArticleDOI
Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study
Judith Haschka,Matthias Englbrecht,Axel J. Hueber,Bernhard Manger,Arnd Kleyer,Michaela Reiser,Stephanie Finzel,Hans Peter Tony,Stefan Kleinert,Martin Feuchtenberger,Martin Fleck,K. Manger,Wolfgang Ochs,M. Schmitt-Haendle,Joerg Wendler,F. Schuch,Monika Ronneberger,Hanns Martin Lorenz,H. Nuesslein,Rieke Alten,Winfried Demary,Joerg Henes,Georg Schett,Juergen Rech +23 more
TL;DR: This randomised controlled study testing three different treatment strategies in patients with RA in sustained remission demonstrated that more than half of the patients maintain in remission after tapering or stopping conventional and biological DMARD treatment.
Journal ArticleDOI
Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment.
Juergen Rech,Axel J. Hueber,Stephanie Finzel,Matthias Englbrecht,Judith Haschka,Bernhard Manger,Arnd Kleyer,Michaela Reiser,Jayme Fogagnolo Cobra,Camille P. Figueiredo,Hans-Peter Tony,Stefan Kleinert,Joerg Wendler,F. Schuch,Monika Ronneberger,Martin Feuchtenberger,Martin Fleck,K. Manger,Wolfgang Ochs,M. Schmitt-Haendle,Hanns-Martin Lorenz,H. Nuesslein,Rieke Alten,Joerg Henes,Klaus Krueger,Georg Schett +25 more
TL;DR: MBDA improved the prediction of relapses in patients with RA in stable remission undergoing DMARD tapering, and if combined with ACPA testing, allowed prediction of relapse in more than 80% of the patients.
Journal ArticleDOI
Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs
Camille P. Figueiredo,Holger Bang,Jayme Fogagnolo Cobra,Matthias Englbrecht,Axel J. Hueber,Judith Haschka,Bernhard Manger,Arnd Kleyer,Michaela Reiser,Stephanie Finzel,Hans-Peter Tony,Stefan Kleinert,Joerg Wendler,F. Schuch,Monika Ronneberger,Martin Feuchtenberger,Martin Fleck,K. Manger,Wolfgang Ochs,M. Schmitt-Haendle,Hanns-Martin Lorenz,H. Nuesslein,Rieke Alten,Joerg Henes,Klaus Krueger,Juergen Rech,Georg Schett +26 more
TL;DR: The data suggest that the pattern of antimodified protein antibody response determines the risk of disease relapse in patients with RA tapering DMARD therapy.
Journal ArticleDOI
Advanced machine learning for predicting individual risk of flares in rheumatoid arthritis patients tapering biologic drugs.
Asmir Vodencarevic,Koray Tascilar,Fabian Hartmann,Michaela Reiser,Axel J. Hueber,Judith Haschka,Judith Haschka,Sara Bayat,Timo Meinderink,Johannes Knitza,Larissa Valor Méndez,Melanie Hagen,Gerhard Krönke,Jürgen Rech,Bernhard Manger,Arnd Kleyer,Marcus Zimmermann-Rittereiser,Georg Schett,David Simon +18 more
TL;DR: In this paper, a machine learning model was used to predict individual flare probability in rheumatoid arthritis patients tapering bi-modifying anti-rheumatic drugs (bDMARDs) using machine learning methods.
Journal ArticleDOI
Cost-effective Tapering Algorithm in Patients with Rheumatoid Arthritis: Combination of Multibiomarker Disease Activity Score and Autoantibody Status.
Melanie Hagen,Matthias Englbrecht,Judith Haschka,Michaela Reiser,Arnd Kleyer,Axel J. Hueber,Bernhard Manger,Camille P. Figueiredo,Jayme Fogagnolo Cobra,Hans-Peter Tony,Stephanie Finzel,Stefan Kleinert,Jörg Wendler,F. Schuch,Monika Ronneberger,Martin Feuchtenberger,Martin Fleck,K. Manger,Wolfgang Ochs,H.-M. Lorenz,Hubert Nüsslein,Rieke Alten,Jörg Henes,Klaus Krüger,Georg Schett,Jürgen Rech +25 more
TL;DR: Combining MBDA score and ACPA status at baseline may allow risk stratification for successful DMARD tapering and cost-effective use of biologic DMARD in patients in deep remission as defined by the 28-joint count Disease Activity Score using erythrocyte sedimentation rate.